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A gene expression inflammatory signature specifically predicts
multiple myeloma evolution and patients survival
C Botta1, MT Di Martino1, D Ciliberto1, M Cucè1, P Correale2, M Rossi1, P Tagliaferri1 and P Tassone1
Multiple myeloma (MM) is closely dependent on cross-talk between malignant plasma cells and cellular components of the
inflammatory/immunosuppressive bone marrow milieu, which promotes disease progression, drug resistance, neo-angiogenesis,
bone destruction and immune-impairment. We investigated the relevance of inflammatory genes in predicting disease evolution
and patient survival. A bioinformatics study by Ingenuity Pathway Analysis on gene expression profiling dataset of monoclonal
gammopathy of undetermined significance, smoldering and symptomatic-MM, identified inflammatory and cytokine/chemokine
pathways as the most progressively affected during disease evolution. We then selected 20 candidate genes involved in B-cell
inflammation and we investigated their role in predicting clinical outcome, through univariate and multivariate analyses (log-rank
test, logistic regression and Cox-regression model). We defined an 8-genes signature (IL8, IL10, IL17A, CCL3, CCL5, VEGFA, EBI3 and
NOS2) identifying each condition (MGUS/smoldering/symptomatic-MM) with 84% accuracy. Moreover, six genes (IFNG, IL2, LTA,
CCL2, VEGFA, CCL3) were found independently correlated with patients’ survival. Patients whose MM cells expressed high levels of
Th1 cytokines (IFNG/LTA/IL2/CCL2) and low levels of CCL3 and VEGFA, experienced the longest survival. On these six genes, we
built a prognostic risk score that was validated in three additional independent datasets. In this study, we provide proof-of-concept
that inflammation has a critical role in MM patient progression and survival. The inflammatory-gene prognostic signature validated
in different datasets clearly indicates novel opportunities for personalized anti-MM treatment.
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INTRODUCTION
Multiple myeloma (MM) is one of the most common hematologic
malignancies and is characterized by an uncontrolled clonal
proliferation of malignant plasma cells (PCs) within the bone
marrow (BM). MM is considered a multistep disease, as it progress
from monoclonal gammopathy of undetermined significance
(MGUS),1 that evolves in MM in about 1% of cases per year, often
with the intermediate phase of smoldering MM (sMM).2 Although
lacking the clinical features of symptomatic disease, both
MGUS and sMM patients carry the same initial mutations and
most of the chromosomal abnormalities of overt MM, suggesting
that these events are necessary but not sufficient for disease
progression.3,4 The evolution from MGUS to sMM and finally to
MM relies on further complex conditions that include genomic
instability, epigenetic and microenvironmental signals.2,4,5 The
interplay between MM cells and the BM microenvironment
(BMM) is currently under active investigation, and different studies
have pointed out its role in both disease pathogenesis and
progression.3,6 Indeed, MM cells grow and proliferate almost
exclusively within the BM, where they produce an inflammatory/
immunosuppressive milieu, which promotes disease progression,
drug resistance, neo-angiogenesis, bone destruction and immune
escape.7–9
Inflammation has been recently recognized as hallmark of cancer
because of its role in cancer initiation and progression.10 Cytokines
and chemokines produced in the tumor microenvironment by
cancer or cancer-associated cells (such as immune infiltrating cells),
have been reported to support cancer cell growth, and induce
epigenetic changes and genomic instability.11–13
On these bases, we identified an inflammatory-gene signature able
to discriminate the different phases of disease progression. Moreover,
we investigated the prognostic relevance of inflammatory-gene
expression in predicting MM patient survival by analyzing large
annotated gene expression profiling (GEP) datasets.
MATERIAL AND METHODS
Gene expression datasets
GEP data from five different datasets underwent our statistical analysis
(datasets characteristics are reported in Supplementary Table 1): (1)
GSE47552(ref. 2) including GEP data from purified CD138+ cells from BM of
five healthy donors, 20 MGUS, 33 sMM and 41 newly diagnosed MM
patients; (2) GSE9782(ref. 14) including GEP data from 264 pretreated
patients enrolled in phase II and III bortezomib trials; (3) GSE24080(ref. 15)
including GEP data from 559 newly diagnosed MM treated with total
therapy (TT) 2 or 3; (4) GSE57317(ref. 16) including GEP data from 55 pre-
treated patients enrolled in TT6 phase II clinical trial; and (5) GSE2658 (ref. 17)
including GEP data from 559 chemo-naive patients enrolled in TT2 and TT3
clinical trials. According to original studies, gene expression data from
different datasets were normalized independently by using the microarray
suite 5.0 (MAS5, Affymetrix, Santa Clara, CA, USA) algorithm (except for
GSE47552, normalized with the robust multi-array analysis (RMA)
algorithm). GEP data from GSE47552 dataset underwent fold-change (FC)
analysis by using dChip software.18 The comparison analysis tool of
Ingenuity Pathway Analysis (IPA) (Ingenuity System, Redwood city, CA,
USA) was used to evaluate the main pathways modulated during disease
progression from MGUS to sMM and to MM. To fulfill IPA requirements for
this analysis, each condition (MGUS, sMM and MM) was compared to
normal samples (that in this case worked as ‘normalizer’) and then the
three different FC analyses underwent a comparison study to investigate
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the main modulated canonical pathways. A fold-change 41.5 and a
P-value o0.05 were used to include genes in the IPA analysis.
Inflammatory model to discriminate between MGUS/sMM/MM
A shortlist of 20 candidate genes coding for cytokines/chemokines
involved in inflammatory response has been derived by relevant literature,
focusing on B lymphocytes (effector/regulatory) or healthy/malignant PCs:
IL2, IL6, IL8, IL10, IL12A, IL15, IL17A, EBI3 (IL35), CCL2 (MCP1), CCL3
(MIP1a), CCL5 (RANTES), CSF2 (GM-CSF), VEGFA, TNF, NOS2 (iNOS), IFNG,
TNFSF11 (RANK-ligand), LTA (Lymphotoxin A/TNF-b), LTB, TGFB1;19,28
(Supplementary Table 2). The expression level of these genes was
retrieved from each dataset and used for further analyses. When multiple
probes were found to map to the same gene, the one with the highest
values was used. All genes were evaluated for their capability to
discriminate between MGUS/sMM/MM through univariate analysis by
Figure 1. (a) Comparison analysis to investigate the main affected canonical pathway during evolution from MGUS to MM. Color intensity
represents the degree of significance of pathway modulation in each disease condition. (b) Probe fluorescence intensity of the eight genes
that resulted significantly associated with MGUS, sMM and MM condition after multinomial logistic regression analysis The range and interval
of all axes was automatically determined to evidence differences in fluorescence distribution between different conditions. (c) Percentages of
patients correctly classified according to the 8-genes model. (d) ROC curves built to evaluate the accuracy of the 8-genes model.
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using a non-parametric Kruskal–Wallis one-sided ANOVA. Subsequently, all
significant variables (Po0.05), underwent a multinomial logistic regression
model, where the variables significantly associated with the disease status
were identified by using a backward Wald approach. The receiving
operating characteristic (ROC) curve analysis was used to evaluate the
performance of the model for disease status prediction in terms of
sensitivity and specificity.
Construction of an inflammatory prognostic score
We used the GSE9782 dataset (excluding patients treated with dex-
amethasone alone) to build an inflammatory prognostic score, whereas
GSE24080, GSE57317 and GSE2658 datasets were used to validate the
model. Each of the 20 selected genes was divided into three categories
according to their expression (low/mid/high expression, using the 33th
and 66th percentile as cut-offs) and was evaluated in a univariate analysis
for its association with patients’ overall survival (OS) by using the log-rank
test. Subsequently, only variables associated with survival (P-value selected
at o0.1) were entered into a Cox proportional hazard regression model.
The variables resulted independently associated with survival (Po0.05)
were further used to build a prognostic score and patients were divided
into three prognostic groups (PGs) (high risk/mid risk/low risk). ROC curve
and log-rank test were used to evaluate the prognostic performance of
the model.
Statistical analysis
Parametric and non-parametric tests were used to compare means
between groups, according to Gaussian or not-Gaussian distribution of
the variable evaluated. Survival curves were built through the Kaplan–
Meier method and differences between groups evaluated through the log-
rank test. Multivariate analysis was performed through the logistic
regression model for classification or Cox-regression model for survival
analysis. All statistical analyses were performed though SPSS 20.0 and
Graphpad PRISM 6 statistic packages. This work follows reporting
recommendations for tumor marker prognostic studies (REMARK).29
RESULTS
An 8-genes signature correctly differentiates between MGUS, sMM
and MM
We compared GEP data of healthy donors, MGUS, sMM and MM
patients from GSE47552 dataset to investigate the main canonical
pathways modulated during disease progression. As shown in
Figure 1a, IPA comparison between different disease conditions
shows inflammatory and cytokine/chemokine signaling pathways
as the most significantly modulated during the transition from
MGSU to MM. This finding provided us the rational for selecting 20
candidate genes, known to be involved in B cells/PCs-mediated
inflammation, and evaluating their relevance in predicting disease
progression. The flow chart for the construction of the model is
reported in Supplementary Figure 1. In univariate analysis, we
investigated the 20 selected genes for their capability to correctly
discriminate between the three disease states. We found 10 genes
(IL15, IL17A, EBI3, CCL3, CCL5, LTB, CSF2, IFNG, RANKl and NOS2)
with highly significant differential expression (Po0.01), 6 genes
(IL2, IL8, IL10, TNF, TGFB1 and VEGFA) with significant differential
expression (Po0.05 but 40.01) and 5 genes (IL6, IL12A, CCL2,
LTA) not correlated with the disease status according to Kruskal–
Wallis ANOVA test (Table 1). Subsequently, all significant variables
underwent a multinomial logistic regression model (parameters
and coefficients reported in Supplementary Table 3) that
identified 8 genes (IL8, IL10, IL17A, CCL3, CCL5, VEGFA, EBI3 and
NOS2) (Figure 1b) whose combination correctly assigned 84% of
subjects to disease groups (Figure 1c). The model robustness was
further confirmed by the high AUC (near 0.9) reported for the
three ROC curves (Figure 1d).
Table 1. Univariate association of inflammatory genes with disease
conditions




IL2 MGUS 2.59 0.02
sMM 2.62 0.31
MM 2.67 0.01
IL6 MGUS 5.02 0.42
sMM 5.30 0.50
MM 5.56 0.20
IL8 MGUS 8.94 0.03
sMM 9.22 0.33
MM 8.56 0.15
IL10 MGUS 4.21 0.03
sMM 4.43 0.74
MM 4.54 0.02
IL12A MGUS 5.56 0.07
sMM 5.96 0.05
MM 5.93 0.03




sMM 5.51 o0.01 o0.01
MM 5.65 o0.01
EBI3 MGUS 5.62
sMM 5.40 o0.01 o0.01
MM 5.62 0.71
CCL2 MGUS 6.20 0.10
sMM 5.93 0.18
MM 6.41 0.64
CCL3 MGUS 7.55 o0.01
sMM 8.41 0.17
MM 9.10 o0.01
CCL5 MGUS 7.06 o0.01
sMM 7.49 0.20
MM 6.71 0.06
LTA MGUS 5.122 0.11
sMM 5.044 0.19
MM 4.984 0.04
LTB MGUS 8.05 o0.01
sMM 7.79 o0.01
MM 7.83 o0.01
CSF2 MGUS 3.26 o0.01
sMM 3.19 0.13
MM 3.34 0.13
TNFA MGUS 5.34 0.05
sMM 5.42 0.75
MM 5.55 0.06
IFNG MGUS 3.57 o0.01
sMM 4.16 o0.01
MM 3.60 0.51
TGFB1 MGUS 7.62 0.05
sMM 8.01 0.01
MM 7.99 0.04
RANKL MGUS 3.71 0.01
sMM 3.59 0.02
MM 3.71 0.57
VEGFA MGUS 6.18 0.04
sMM 6.53 0.07
MM 6.54 0.01
NOS2 MGUS 4.87 o0.01
sMM 4.80 0.22
MM 4.95 0.15
Abbreviations: MGUS, monoclonal gammopathy of undetermined sig-
nificance; MM, multiple myeloma; sMM, smoldering MM. This table include
the results of Mann–Whitney (MW) and Kruskall–Wallis (KW) tests in which
each of the 20 candidates genes were evaluated for their association with
each disease condition. Values in bold are statistically significant.
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A 6-genes inflammatory score predicts survival of MM patients
We further investigated whether selected inflammatory genes
could be associated with MM patients’ survival. To do that, we
used as a training set for our model the GSE9782 dataset (flow
chart is reported in Figure 2). We first performed a univariate
survival analysis (log-rank test) to identify inflammation-related
genes, whose expression was correlated with patients’ survival, to
select candidates for multivariate analysis. A total of 12 genes
were identified and results are reported in Supplementary Table 4.
We excluded IL6 from subsequent analysis due to excessive
cross of survival curves. To evaluate if selected genes indepen-
dently predicted patients’ survival, we performed a multivariate
regression analysis. Only 6 genes (IFNG, IL2, CCL2, CCL3, VEGF and
LTA) showed independent predictive power (Supplementary
Figure 2A). Of them, a higher expression of IFNG, IL2, CCL2 and
LTA was associated with good prognosis, whereas a higher
expression of CCL3 or VEGFA was associated with worse survival.
Because of the fact that Cox-regression model reported a similar
relative contribution (positive or negative) for each variable (data
not shown) and to the need of building a model suitable for
different gene expression platforms, we added a score to each
gene (low expression = 1, mid expression = 2 and high expres-
sion = 3) and then built a prognostic risk score (RS) as follows: IFNG
+IL2+CCL2+LTA—VEGFA–CCL3. The RS may assume 13 different
values and its capability to discriminate patients surviving more
than 12, 18 or 24 months is shown in Supplementary Figure 2B.
According to 33th and 66th percentile of the RS, patients were
divided into three PGs: HR (high risk) = RS − 2/+2; IR (intermediate
risk) = RS 3/5; LR (low risk) = RS 6/10 (Figure 3a). The prognostic
model was strongly associated with survival, with patients in LR
group not reaching the median OS and experiencing a Hazard
Ratio reduction of 77% (Figure 3a). Furthermore, a higher
prognostic score (low risk) was significantly associated with high
albumin and low B2-microglobulin levels, and consequently to a
low ISS score. Interestingly, the LR group presented a low CRP
value (Figure 3b).
Validation of the inflammatory prognostic score in different
patient datasets
To confirm the robustness of the inflammatory prognostic score,
we validated our model in three independent datasets: GSE24080,
GSE57317 and GSE2658. The GSE24080 only reported survival data
in term of OS424 or o24 months, anyway patients belonging to
the LR group presented a significant higher number of long
survival patients as compared to both IR and HR groups (Figure 4a;
Supplementary Figure 3). Both GSE57317 and GSE2658 reported
survival data, and in both datasets patients in the HR group
presented a significant shorter survival thus validating our model
(Figures 4b and c; Supplementary Figure 3).
DISCUSSION
In this study, we investigated the role of 20 inflammation-related
genes in predicting disease evolution and MM patients’ survival.
Firstly, we analyzed the expression of these genes in a GEP
microarray dataset from purified PCs of MGUS-sMM-MM patients.
Through a multinomial logistic regression analysis, we identified
an 8-genes signature able to discriminate with high precision the
three different conditions. We found a consistent upregulation of
CCL3, VEGFA and NOS2 in MM as compared with MGUS, which are
known to attract myeloid cells such as neutrophils and monocytes
at the inflammatory site.30,31 Notably, we found a consistent
decrease of LTA and LTB during disease evolution; these genes
code for cytokines (TNF-β and TNF-C, respectively) essential for
adaptive immune-response due to their role in follicular dendritic
cell maturation, Th1 polarization and organization and activation
of secondary as well as tertiary lymphoid organs.23 These findings
led us to hypothesize that PCs progressively shift the BMM toward
a pro-inflammatory and immunosuppressive shape, which drives
disease evolution.
We then evaluated whether differential expression of selected
inflammatory genes could predict patients survival. We identified
IFNG, IL2, LTA and CCL2 as correlated with favorable prognosis,
whereas CCL3 and VEGFA were associated with adverse outcome.
On these bases, we built a prognostic risk score with patients
classified into three PGs. We validated our prognostic score in
three independent cohorts of patients with MM. Patients who
experienced the longest survival presented high levels of IFNG,
IL2, LTA and CCL2; the first three code for main cytokines driving
Th1 response and T/NK-cell proliferation and cytotoxic activity.32,33
Conversely, CCL2 has been described to have a role in both tumor
progression and immune activation.34 Indeed, different studies
reported its role in angiogenesis and MM homing to the BM as
well as in the recruitment of tumor-promoting macrophages and
anti-tumor cytotoxic γδ T lymphocytes.34,35 It is conceivable that
increased production of all these cytokines by MM cells make
CCL2 predominantly tumor-suppressive, resulting in the promo-
tion of Th1 response, which might lead to increased patients
survival.36 On the other side, we identified VEGFA and CCL3 as
overexpressed in patients with adverse outcome. VEGFA, which is
secreted by MM cells and components of the BMM, promotes neo-
angiogenesis, MM cells survival, migration, and has an immune-
suppressive role.37 CCL3 is produced mainly by MM cells and acts
as chemoattractant for monocyte-derived cells which, within the
BMM, differentiate into macrophages or osteoclasts. These cells in
turn promote inflammation, angiogenesis, osteolytic lesions and
immune-response impairment.38 Both cytokines highlight the
inflammatory microenvironment and are involved in MM-
associated bone disease, worsening patients’ prognosis.39,40
Inflammation is an hallmark of cancer development.41 Indeed,
different studies have already demonstrated a strong correlation
between chronic inflammation and increased risk of cancer.
Moreover, the chemopreventive role of aspirin and other
NSAIDs has been clearly demonstrated.42 Along this line, recent
clinical trials revealed a promising therapeutic activity of anti-
inflammatory compounds such as aspirin and curcumin in both
MGUS and sMM patients.43,44
Furthermore, inflammation could also reduce the activity of
current anti-cancer treatment (both cytotoxic and immunothera-
pies), by impairing effective immune-response against tumor
cells.12,45–48 Accordingly, there is a growing body of evidence
underlining that an immunogenic response following anti-cancer
therapies produce long-lasting responses.46,49–52 This event
implies immunogenic cell death (ICD), which is characterized by
generation of an immune-activating microenvironment where
Figure 2. Algorithm for prognostic score identification.
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dying cells (i) are recognized by professional antigen-presenting
cells (APCs) due to the surface expression of several ‘eat-me’
molecules such as calreticulin and/or HSP70/90; and (ii) attract and
activate APCs to promote an efficient anti-tumor Th1/γδ T/CD8 cell
response, by releasing ATP, HMGB1 and type 1 IFNs.53 On these
bases, we believe that a BMM where MM cells secrete Th1
cytokines (IFNG, IL2, LTA), attract γδ T cells (through CCL2
production) and produce low amount of inflammatory/immuno-
suppressive cytokines (VEGF and CCL3),54,55 represents the best
condition for therapeutic activity of ICD-inducers bortezomib56 or
doxorubicin,57 and of the immunomodulatory drugs thalidomide,
lenalidomide and pomalidomide.9
Although our results clearly underscore the role of several
inflammatory genes in MM pathogenesis, we underline several
limitations of our study. First of all, our analysis is performed on
candidate genes. This may however represent a strength, due to
the fact that genes are selected on the basis of well-defined
pathways, and a weakness, due to the fact that information
related to uninvestigated genes is unavoidably lost. Nevertheless,
we demonstrated that inflammatory pathways are indeed among
the most modulated during disease evolution and we validated
our prognostic score in three different annotated datasets. In
addition, we cannot exclude the influence of the small percentage
of non-myeloma cells on the results of our analysis. Indeed, we
tried to reduce this bias by working on genes that code for
molecules produced by PCs or B cells. Further limitations are that
our model is trained and validated on microarray based platform,
and that the disease evolution model still need to be validated.
Indeed, our findings should be considered ‘hypothesis-generating’
and future prospective validation of the models must rely on
different technologies, such as qRT-PCR and/or RNAseq.
Nonetheless, with our research, we identified potential targets,
which might be of major relevance for antagonizing the disease
evolution or for the treatment of symptomatic-MM patients. It is
important to underscore that the simultaneous targeting of these
different pathways rather than the single molecules inhibition
might effectively reduce inflammation and induce Th1/γδ/CD8
response, finally resulting in increased patients’ survival. To this
aim, current research will gain the best advantage from the new
emerging scenario of functional network of non-coding RNAs,
such as miRNAs and long non-coding RNAs, that already
demonstrated their role in the control of different (immune-) cell
functions and in cancer biology, and are approaching the clinical
side.58–61 In conclusion, we provide proof-of-concept that MM
Figure 3. (a) On the left, heatmap reporting probe fluorescence intensity of six selected genes for each patient evaluated in accordance with
its survival, prognostic score and PG. On the right, Kaplan–Meier curves reporting patients’ survival according to their PG. Median survival and
Hazard ratio values are reported below the curves. (b) Evaluation of correlation between PGs, the two variables forming the international
staging system (albumin and B2-microglobulin) and CRP (c-reactive protein).
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cells drive a pro-inflammatory effect in the BMM, which is relevant
in the disease evolution. The inflammatory signatures here
reported, which differentiate disease phases and offer a novel
prognostic tool, might be relevant for the design of novel
individualized treatment of MM.
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